Breaking Stories

The Ratings Game: Biogen stock rockets to 6-year high after Alzheimer’s drug gets FDA OK


Shares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration’s broad labeling that came with the approval of the biotechnology company’s Alzheimer’s drug.

Metals Stocks: Gold prices notch back-to-back gains, but settle below $1,900/oz.

Previous article

: Bitcoin faces fresh scrutiny as police call for new powers to freeze crypto assets in the U.K.

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *